Aiforia Technologies Plc – Managers’ Transactions
Aiforia Technologies Plc, Company Release, Managers’ Transactions, December 19, 2023 09:00 a.m. EET
____________________
Person subject to the notification requirement
Name: Ropponen, Tuomas Antero
Position: Other senior manager
Issuer: Aiforia Technologies Plc
LEI: 743700TJRVBX7420Y723
Notification type: INITIAL NOTIFICATION
Reference number: 743700TJRVBX7420Y723_20231215132059_16
____________________________________________
Transaction date: 2023-12-15
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Instrument name: Aiforia Technologies 2022 II 7 options
Nature of the transaction: ACCEPTANCE OF A STOCK OPTION
(X) Linked to stock option programme
Transaction details
(1): Volume: 50000 Unit price: 0.00 EUR
Aggregated transactions
(1): Volume: 50000 Volume weighted average price: 0.00 EUR
Further inquiries
Veli-Matti Parkkonen, CFO, Aiforia Technologies Plc
tel. +358405009878
https://investors.aiforia.com/
Certified Adviser
UB Securities Ltd
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.
Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient.
Find out more at www.aiforia.com